---
title: "Retinal Surgery"
order: 3
category: "Ophthalmology"
---

# Vitreoretinal Surgery

## Overview

Vitreoretinal surgery addresses pathology of the posterior segment, including retinal detachment, macular holes, epiretinal membranes, vitreous hemorrhage, and complications of diabetic retinopathy. The cornerstone procedure is pars plana vitrectomy (PPV), which removes the vitreous gel to access and treat the retina. Modern vitreoretinal surgery utilizes microsurgical techniques with small-gauge instrumentation (23-, 25-, or 27-gauge) allowing sutureless surgery and faster recovery. Successful outcomes require precise surgical technique, understanding of vitreoretinal anatomy and pathophysiology, and meticulous postoperative management.

## Vitreoretinal Anatomy

### Vitreous

**Structure**:
- **Composition**: 99% water, collagen fibrils, hyaluronic acid
- **Volume**: ~4mL
- **Function**: Maintains globe shape, optical clarity, metabolic support to retina (in youth)

**Attachments**:
- **Strongest**: Vitreous base (ora serrata), optic disc margin
- **Moderate**: Macula, retinal vessels
- **Posterior vitreous cortex**: Adherent to internal limiting membrane (ILM) of retina

**Posterior Vitreous Detachment (PVD)**:
- Age-related liquefaction of vitreous (syneresis)
- Vitreous cortex separates from retina
- **Symptoms**: Flashes (traction on retina), floaters (condensed collagen)
- **Complications**: Retinal tear (10-15%), retinal detachment (if untreated tear)

### Retina

**Layers** (from internal to external):
1. Internal limiting membrane (ILM)
2. Nerve fiber layer (ganglion cell axons)
3. Ganglion cell layer
4. Inner plexiform layer
5. Inner nuclear layer
6. Outer plexiform layer
7. Outer nuclear layer (photoreceptor nuclei)
8. External limiting membrane
9. Photoreceptor layer (rods and cones)
10. Retinal pigment epithelium (RPE)

**Blood Supply**:
- **Inner retina**: Central retinal artery branches
- **Outer retina (photoreceptors)**: Choriocapillaris (choroid)

**Macula**: Central 5-6mm, responsible for central vision, color vision
- **Fovea**: Center of macula (1.5mm), highest cone density, best visual acuity
- **Foveola**: Central 0.35mm, cones only, avascular

**Peripheral Retina**: Extends to ora serrata, responsible for peripheral vision

### Retinal Pigment Epithelium (RPE)

- Single layer of pigmented cells
- **Functions**: Phagocytose photoreceptor outer segments, vitamin A metabolism (visual cycle), blood-retina barrier, growth factor secretion
- Adherent to Bruch's membrane (basement membrane separating RPE from choroid)

## Pars Plana Vitrectomy (PPV)

### Principle

Remove vitreous gel to access retina, relieve traction, remove opacities, create tamponade

### Indications

- **Retinal detachment** (rhegmatogenous, tractional)
- **Vitreous hemorrhage** (diabetic retinopathy, trauma, retinal vascular occlusion)
- **Macular hole**
- **Epiretinal membrane**
- **Diabetic tractional retinal detachment**
- **Endophthalmitis** (infectious)
- **Intraocular foreign body**
- **Dislocated IOL**
- **Complications of cataract surgery** (dropped nucleus)

### Instrumentation

**Gauge**: Entry site size
- **20-gauge**: 0.9mm (older, requires sclerotomies with sutures)
- **23-gauge**: 0.6mm (sutureless)
- **25-gauge**: 0.5mm (most common, sutureless)
- **27-gauge**: 0.4mm (ultra-small, sutureless)

**Smaller gauge advantages**: Less trauma, faster recovery, sutureless
**Disadvantages**: Less rigid instruments, smaller infusion (longer case), higher risk of hypotony

**Trocar System**: Insert cannulated trocars through sclera at pars plana (3.5mm from limbus in phakic, 3.0mm in pseudophakic/aphakic)

### Surgical Technique

**Anesthesia**: Local (retrobulbar or peribulbar) or general

**Patient Positioning**: Supine (may turn prone post-op for gas tamponade)

**Steps**:

1. **Sclerotomy Creation**:
   - Insert 3 trocars at pars plana (4, 8, 10 o'clock positions)
   - **Infusion cannula**: Inferior (maintains IOP during surgery)
   - **Light pipe**: Illumination
   - **Vitrector**: Cutting and aspirating instrument

2. **Core Vitrectomy**:
   - Vitrector removes central vitreous gel
   - **Vitrector**: Guillotine-style cutter (500-7500 cuts per minute)

3. **Posterior Vitreous Detachment Induction** (if not already present):
   - Separate vitreous cortex from retina (using suction or forceps at optic disc)
   - Critical for many pathologies (relieves traction)

4. **Peripheral Vitrectomy**:
   - Remove peripheral vitreous to vitreous base (with scleral depression)
   - **Scleral depression**: Assistant indents sclera externally to visualize far periphery

5. **Pathology-Specific Steps**:
   - **Membrane peeling**: Epiretinal membrane, ILM (macular hole)
   - **Retinal tear treatment**: Laser or cryotherapy around tear
   - **Drainage of subretinal fluid**: If retinal detachment
   - **Endolaser**: Laser photocoagulation to retina (treat tears, create adhesion)

6. **Tamponade** (if needed):
   - **Gas** (SF6, C3F8): Expands, provides tamponade for retinal detachment/macular hole (absorbs over 1-8 weeks)
   - **Silicone oil**: Long-term tamponade (requires removal surgery), used for complex detachments
   - **Purpose**: Keeps retina opposed to RPE while healing

7. **Closure**:
   - Remove trocars, confirm sclerotomy sites self-seal (sutureless technique)
   - Subconjunctival antibiotics and steroids

**Fluid-Air Exchange**: Replace vitreous cavity fluid with air (then gas or silicone oil)
- Allows internal drainage of subretinal fluid
- Gas tamponade for retinal reattachment

### Postoperative Care

**Positioning** (if gas tamponade):
- **Face-down positioning**: 23 hours/day for 1-2 weeks (for macular hole, inferior retinal detachment)
- **Head positioning**: Tailored to break/hole location (gas bubble floats to highest point, tamponades break)

**Medications**:
- **Topical antibiotics**: 1 week
- **Topical steroids**: Taper over 4-6 weeks
- **Cycloplegics**: Reduce pain, inflammation

**Activity Restrictions**:
- **No air travel** with gas bubble (gas expands at altitude → severe IOP elevation)
- **Avoid nitrous oxide anesthesia** (expands gas bubble)
- Duration depends on gas type: SF6 (2-3 weeks), C3F8 (6-8 weeks)

**Follow-Up**:
- POD 1: IOP, retinal attachment
- Weekly until gas absorbs
- Monitor for complications (redetachment, elevated IOP, cataract)

### Complications

**Intraoperative**:
- **Retinal tear/break**: Iatrogenic (0.5-5%)
- **Hemorrhage**: Vitreous, suprachoroidal
- **Choroidal effusion**: Hypotony-related

**Early Postoperative**:
- **Elevated IOP**: Gas expansion, pupillary block, steroid response
  - **Management**: Antiglaucoma drops, gas tap/release if severe
- **Hypotony**: Sclerotomy leak, cyclodialysis
- **Endophthalmitis**: Very rare (<0.05%)
- **Vitreous hemorrhage**: Re-bleeding

**Late**:
- **Cataract**: Nearly universal in phakic patients (70-90% within 2 years)
  - Nuclear sclerotic cataract from vitrectomy
- **Retinal detachment**: Recurrent or new break (5-10%)
- **Proliferative vitreoretinopathy (PVR)**: Scar tissue formation on retina (5-10% after RD surgery)
- **Epiretinal membrane**: Scar tissue on macula
- **Silicone oil complications**: Emulsification, glaucoma, corneal decompensation, requires removal

## Rhegmatogenous Retinal Detachment

### Pathophysiology

**Rhegmatogenous**: From Greek "rhegma" (break/tear)
- **Sequence**: Retinal break → Vitreous fluid enters subretinal space → Retina separates from RPE
- **Requires**: 1) Vitreous liquefaction, 2) Vitreous traction, 3) Retinal break

### Risk Factors

- **High myopia**: Thin retina, lattice degeneration
- **Posterior vitreous detachment**: Causes retinal tears (10-15% with symptomatic PVD)
- **Trauma**: Blunt or penetrating
- **Prior cataract surgery**: Especially complicated cases
- **Lattice degeneration**: Peripheral retinal thinning (6-10% population)
- **Family history**

### Clinical Presentation

**Symptoms**:
- **Flashes** (photopsia): Vitreous traction on retina
- **Floaters**: Condensed vitreous, hemorrhage, pigment
- **Shadow/curtain**: Visual field defect (advancing detachment)
- **Decreased central vision**: If macula detached ("macula-off")

**Signs**:
- **Retinal elevation**: Gray, convex retina with subretinal fluid
- **Retinal breaks**: Horseshoe tears (most common), round atrophic holes, dialysis
- **Pigment in vitreous** ("tobacco dust"): Shafer's sign
- **Relative afferent pupillary defect (RAPD)**: If extensive detachment

**Macula Status**:
- **Macula-on**: Central vision preserved, better prognosis
- **Macula-off**: Central vision loss, permanent vision loss common even if repaired

### Treatment

**Pneumatic Retinopexy** (selected cases):
- **Indications**: Single break in superior 8 o'clock hours, macula-on or recently off, compliant patient
- **Technique**: Office-based, inject gas bubble into vitreous, position patient (gas floats to tamponade break), laser/cryotherapy to seal break
- **Success**: 70-80% single procedure, 90%+ with reintervention
- **Advantages**: Office-based, quick recovery
- **Disadvantages**: Strict positioning required, new breaks can occur

**Scleral Buckle**:
- **Principle**: Indent sclera to relieve vitreous traction, close retinal break
- **Technique**: Silicone sponge or band sutured to sclera over break location, cryotherapy or laser to seal break
- **Indications**: Younger patients (phakic), peripheral breaks, selected detachments
- **Success**: 85-90%
- **Complications**: Refractive change (myopic shift), diplopia, scleral perforation, infection

**Pars Plana Vitrectomy**:
- **Indications**: Complex detachment (PVR, multiple breaks, posterior breaks), macula-off, failed other procedures, combined with other pathology
- **Technique**: Vitrectomy + endolaser + gas/silicone oil tamponade
- **Success**: 85-95% single procedure
- **Complications**: Cataract (near universal), PVR, redetachment

**Combined Scleral Buckle + Vitrectomy**: Complex cases

### Outcomes

**Anatomic success**: 90-95% retinal reattachment (may require multiple procedures)
**Visual outcomes**:
- **Macula-on**: 80-90% return to baseline vision
- **Macula-off**: Variable, 40-70% achieve ≥20/50 vision (depends on duration of detachment)
- **Duration critical**: Macula-off >1 week significantly worse outcomes

## Macular Hole

### Pathophysiology

Full-thickness defect in fovea from anteroposterior and tangential vitreous traction

### Stages (Gass Classification)

- **Stage 1**: Foveal detachment (impending hole)
- **Stage 2**: Small full-thickness hole (<400 μm)
- **Stage 3**: Large full-thickness hole (>400 μm)
- **Stage 4**: Full-thickness hole with complete PVD

### Clinical Presentation

- **Central scotoma** (blind spot)
- **Metamorphopsia** (distortion)
- **Decreased central vision** (typically 20/80 to 20/200)

### Diagnosis

**OCT** (optical coherence tomography): Gold standard
- Shows full-thickness defect, measurements

### Treatment

**Pars Plana Vitrectomy**:
- **Steps**:
  1. Vitrectomy + PVD induction
  2. **ILM peeling**: Remove internal limiting membrane around hole (reduces re-opening risk)
  3. Fluid-gas exchange
  4. **Gas tamponade**: SF6 or C3F8
- **Postoperative positioning**: Face-down 1-2 weeks (critical for closure)

**Closure Rate**: 85-95% (single procedure)
**Visual Improvement**: 70-80% improve ≥2 lines, limited by photoreceptor damage

## Epiretinal Membrane

### Pathophysiology

Cellophane-like scar tissue on retinal surface (ILM), contracts → retinal distortion

### Etiology

- **Idiopathic** (most common): Age-related
- **Secondary**: Prior retinal detachment repair, uveitis, trauma, vascular occlusion

### Clinical Presentation

- **Asymptomatic** (early)
- **Metamorphopsia** (wavy vision): Most common symptom
- **Decreased vision**: If severe

**Signs**: Retinal wrinkling, vascular tortuosity, macular edema

### Treatment

**Observation**: If minimal symptoms
**Vitrectomy with Membrane Peeling**:
- **Indications**: Significant visual symptoms, progressive vision loss
- **Technique**: PPV + membrane peeling (± ILM peeling)
- **Outcomes**: 70-90% improve ≥1-2 lines vision, metamorphopsia improves (may persist)

## Diabetic Retinopathy

### Vitrectomy Indications

- **Vitreous hemorrhage**: Non-clearing (>2-3 months) or severe
- **Tractional retinal detachment**: Involving or threatening macula
- **Combined tractional-rhegmatogenous detachment**
- **Anterior segment neovascularization**: Severe (rubeosis iridis)

### Surgical Considerations

**Complex Cases**:
- Fibrovascular tissue adherent to retina (high risk of iatrogenic breaks)
- Extensive laser needed intraoperatively

**Technique**:
- PPV + membrane delamination/segmentation
- Endolaser panretinal photocoagulation (PRP) if not previously done
- Gas or silicone oil tamponade (if retinal detachment)

**Postoperative**:
- Anti-VEGF injections (reduce neovascularization)
- Continued diabetes management

**Outcomes**: Variable (depends on baseline vision, macular involvement, proliferative changes)

## Endophthalmitis

### Definition

Intraocular infection (bacterial or fungal)

### Classification

**Acute Post-Operative** (most common):
- Onset: 1-7 days after cataract surgery or other intraocular surgery
- **Organisms**: Staph epidermidis (70%), Staph aureus (10%), Streptococcus, gram-negatives
- **Presentation**: Pain, vision loss, hypopyon, vitreous haze

**Chronic Post-Operative**:
- Onset: Weeks to months
- **Organism**: Propionibacterium acnes, fungi
- **Presentation**: Indolent inflammation, white plaque

**Endogenous**: Hematogenous spread from systemic infection (rare)

**Bleb-Associated**: After trabeculectomy

**Post-Traumatic**: Open globe injury

### Management

**Endophthalmitis Vitrectomy Study (EVS)** guidelines:

**Vitreous Tap and Inject** (office or OR):
- **Tap**: Aspirate vitreous for culture
- **Inject**: Intravitreal antibiotics immediately
  - **Vancomycin** 1mg/0.1mL (gram-positive coverage)
  - **Ceftazidime** 2.25mg/0.1mL (gram-negative coverage)
  - Add **Amphotericin B** 5-10μg if fungal suspected

**Vitrectomy**:
- **Indications**: No light perception vision at presentation, severe cases
- **EVS**: Vitrectomy improved outcomes in LP vision, no benefit if better vision (tap and inject equivalent)

**Systemic Antibiotics**: Controversial (poor intraocular penetration, EVS showed no benefit)

**Topical Antibiotics and Steroids**: Fortified drops

**Re-Injection**: If poor response at 48 hours

**Prognosis**:
- **Staph epidermidis**: Good (70% achieve ≥20/40)
- **Staph aureus, Streptococcus, gram-negatives**: Poor (50% <20/200)

## Special Techniques

### Internal Limiting Membrane (ILM) Peeling

**Purpose**: Remove scaffold for epiretinal membrane regrowth, macular hole closure
**Technique**: Stain with dye (indocyanine green, brilliant blue), peel with forceps
**Complications**: Retinal hemorrhage, DONFL (dimples, arcuate defects from trauma)

### Scleral Buckle

**Indications**: Rhegmatogenous RD (especially young phakic patients), retinal dialysis
**Technique**: Silicone sponge or encircling band sutured to sclera
**Complications**: Diplopia, myopic shift, infection, erosion

### Heavy Liquids (Perfluorocarbon)

**Use**: Flatten retina intraoperatively (giant retinal tears, RD), subretinal hemorrhage displacement
**Must remove**: Toxic if retained long-term

### Subretinal Injection

**t-PA**: Tissue plasminogen activator for subretinal hemorrhage (break up clot)
**Anti-VEGF**: Submacular injection for neovascular AMD (experimental)

## Outcomes

### Retinal Detachment

- **Anatomic success**: 90-95%
- **Visual success**: Variable (macula-on better outcomes)

### Macular Hole

- **Closure**: 85-95%
- **Vision improvement**: 70-80% improve ≥2 lines

### Epiretinal Membrane

- **Vision improvement**: 70-90% improve, distortion often persists

### Diabetic Vitrectomy

- **Visual improvement**: 50-70% (depends on baseline)
- **Complication rate**: Higher (10-20% redetachment, re-hemorrhage)

## Key Points

- Pars plana vitrectomy cornerstone of vitreoretinal surgery; uses small-gauge (23-,25-,27-G) sutureless trocars for minimal trauma
- Three-port system: infusion cannula (maintain IOP), light pipe, vitrector (cut and aspirate vitreous)
- Rhegmatogenous retinal detachment requires retinal break + vitreous traction + liquefaction; macula-off duration critical for visual prognosis
- Treatment options for RD: pneumatic retinopexy (office-based, 70-80% success), scleral buckle (85-90%), vitrectomy with gas/oil tamponade (90-95%)
- Macular hole treatment: vitrectomy + ILM peeling + gas tamponade with face-down positioning 1-2 weeks; 85-95% closure rate
- Gas tamponade (SF6 absorbs 2-3 weeks, C3F8 absorbs 6-8 weeks) contraindications: air travel, nitrous oxide anesthesia (gas expansion)
- Epiretinal membrane causes metamorphopsia; treat with vitrectomy + membrane/ILM peeling; 70-90% vision improvement
- Cataract formation near-universal after vitrectomy (70-90% within 2 years in phakic patients)
- Endophthalmitis post-cataract surgery: intravitreal vancomycin + ceftazidime emergently; vitrectomy if light perception only (EVS study)
- Diabetic vitrectomy indications: non-clearing vitreous hemorrhage (>2-3 months), tractional RD threatening macula
- Proliferative vitreoretinopathy (PVR) major cause of failed RD surgery; scar tissue on retina causes redetachment (5-10%)
- ILM peeling reduces macular hole reopening and ERM recurrence but can cause retinal trauma (DONFL defects)

## References

1. American Academy of Ophthalmology. Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration, Preferred Practice Pattern (2019)
2. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. Arch Ophthalmol. 1995;113(12):1479-1496
3. Mitry D, et al. The epidemiology of rhegmatogenous retinal detachment. Br J Ophthalmol. 2010;94(6):678-684
4. Steel DH, Lotery AJ. Idiopathic vitreomacular traction and macular hole: a comprehensive review. Eye (Lond). 2013;27 Suppl 1:S1-S21
5. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Arch Ophthalmol. 1985;103(11):1644-1652
